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Background: High expression of the polymeric immunoglobulin receptor (PIGR) has previously been associated
with a favourable prognosis in a few cancer forms, but its expression and relationship with clinical outcome in
epithelial ovarian cancer (EOC) has not yet been reported. The aim of this study was therefore to examine the
clinicopathological correlates and prognostic significance of PIGR expression in EOC.
Methods: After an initial screening in the Human Protein Atlas portal, a validated antibody was selected for extended
analysis of immunohistochemical PIGR expression in tissue microarrays with tumours from 154 incident cases of EOC
from two pooled prospective population-based cohorts. Subsets of corresponding benign-appearing fallopian tubes
(n = 38) and omental metastases (n = 33) were also analysed. Kaplan-Meier analysis and Cox regression analysis were
applied to examine the impact of PIGR expression on overall survival (OS) and ovarian cancer-specific survival (OCSS).
Results: PIGR expression was significantly higher in fallopian tubes compared to primary tumours and metastases
(p < 0.001) and lower in carcinoma of the serous subtype compared to other carcinomas (p < 0.001). PIGR expression
was significantly associated with lower grade (p = 0.001), mucinous histological subtype (p = 0.002), positive progesterone
receptor expression (p = 0.009) and negative or low Ki-67 expression (p = 0.003). Kaplan-Meier analysis revealed a
significantly improved OS (p = 0.013) and OCSS (p = 0.009) for patients with tumours displaying high expression of PIGR.
These associations were confirmed in unadjusted Cox regression analysis (HR = 0.48; 95% CI 0.26-0.87; p = 0.015 for OS
and HR = 0.43, 95% CI 0.22-0.82; p = 0.011 for OCSS) but did not remain significant after adjustment for age, grade and
clinical stage.
Conclusions: This study provides a first demonstration of PIGR expression in human fallopian tubes, primary EOC
tumours and metastases. High tumour-specific expression of PIGR was found to be associated with a favourable
prognosis in unadjusted, but not in adjusted, analysis. These findings are novel and merit further investigation.
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Epithelial ovarian cancer (EOC) is the fifth most com-
mon cancer type in women in more developed areas and
the most lethal malignancy of the female reproductive
tract [1]. In Sweden, EOC accounts for 3.1% of all can-
cers and 5.9% of all cancer deaths in women [2]. Due to
vague symptomatology and the absence of reliable
screening tests [3], the majority of EOC patients are* Correspondence: karin.jirstrom@med.lu.se
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unless otherwise stated.diagnosed in advanced clinical stages, having stage III
and IV tumours, with poor 5-year survival rates [4].
Hence, there is a need to identify novel diagnostic, prog-
nostic and treatment predictive biomarkers.
Using the Human Protein Atlas (http://www.proteina-
tlas.org) as a tool for antibody based biomarker discovery
[5], the polymeric immunoglobulin receptor (PIGR) was
recently identified as being differentially expressed among
EOC samples, with either negative or strong cytoplasmic
and membranous staining. Thus, we hypothesized that
PIGR might be a putative prognostic biomarker in EOC.ral Ltd. This is an Open Access article distributed under the terms of the Creative
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that binds polymeric immunoglobulin molecules at the
basolateral surface of epithelial cells. The complex is
then transcytosed across the cell to be modified and se-
creted at the apical surface as secretory component (SC)
[6]. SC ensures effective mucosal secretion of polymeric
immunoglobulins [6].
The clinicopathological significance of PIGR has hith-
erto only been investigated in a few studies. PIGR-
negative adenocarcinomas in the distal oesophagus and
gastroesophageal junction have been found to be more
aggressive and to possess higher metastatic potential
compared to adenocarcinomas with high expression of
PIGR [7]. Low expression of PIGR in colorectal cancer
was found to be associated with tumourigenicity [8] and
with poor prognosis [9]. Furthermore, tumour progres-
sion in non-small cell lung cancer is reportedly asso-
ciated with loss of PIGR expression [10]. One study
reported associations between high expression of PIGR
and type 1 endometrial cancer, suggesting a possible
explanation for this less aggressive type [11]. On the
contrary, overexpression of PIGR in hepatitis B-derived
hepatocellular carcinoma has been described to correlate
with higher metastatic potential and poor prognosis
[12]. A study concerning bladder cancer lays forward a
hypothesis that PIGR expression is associated with good
prognosis, however, the study also points out the need
for further research [13]. PIGR expression has not yet
been described in EOC and consequently, this study will
be novel.
The aim of this study was to evaluate the clinicopatho-
logical correlates and prognostic value, of PIGR expression
in EOC, by immunohistochemical (IHC) analysis of 154
EOC samples from two pooled, prospective, population-
based cohorts. The hypotheses of the study were that
PIGR expression would differ in relation to histological
subtype, and that a low expression of PIGR would be asso-
ciated with poor prognosis.
Material and methods
Patients
The study cohort was a merge of all invasive EOC that
had occurred in the two prospective population-based
cohorts Malmö Diet and Cancer Study (MDCS, n = 101)
[14] and Malmö Preventive Project (MPP, n = 108) [15]
until December 31st 2007. The MDCS was initiated in
1991 and enrolled 17 035 healthy women [14,16], with
main objective to obtain information about association
between various dietary factors and cancer incidence
[16]. The MPP was established in 1974 as a preventive
case-finding programme for cardiovascular risk factors
and enrolled 10 902 women [15].
Information on EOC incidence was obtained through
the Swedish Cancer Registry up until December 31 2006,and from The Southern Swedish Regional Tumour Regis-
try for the period of January 1 – December 31 2007.
Thirty-five of the EOC patients participated in both stud-
ies, and archival tumour tissue could be retrieved from
154 (88.5%) of the total number of 174 cases. Information
on clinical stage, following the standardised International
Federation of Gynaecology and Obstetrics (FIGO) classifi-
cation of tumour staging [17], and on treatment data was
retrieved from medical charts. Histopathological data were
obtained from pathology records. Tumours were divided
into four groups according to histological subtype: serous
(n = 90), endometrioid (n = 35), mucinous (n = 12) and
others (n = 17). The latter group included clear cell (n = 9),
Brenner (n = 1) and unknown (n = 7) tumours.
Standard surgical management of EOC patients consisted
of total abdominal hysterectomy, bilateral salpingo-
oophorectomy and omentectomy with cytological evalu-
ation of peritoneal fluid or washings. Routine pelvic
lymphadenectomy was not performed. Standard adjuvant
therapy was platinum-based chemotherapy, from the mid
1990’s in combination with paclitaxel; however, treatment
data was only available for 73 (47.4%) out of the total 154
cases and therefore not considered. Information regarding
residual tumour after surgery was not available.
Median age at diagnosis was 62 (range 47-83). Informa-
tion on cause of death in EOC cases was retrieved from
medical charts and the Swedish Cause-of-Death Registry
up until June 30 2012. Follow-up began at EOC diagnosis
and ended at death, emigration or June 30 2012, which-
ever came first. After a median follow-up of 3.00 years
(range 0–24.63), 122 patients (79.2%) were dead, 112
(72.3%) from ovarian cancer, and 32 (20.8%) were alive.
The study cohort has also been described previously
[18-22]. Ethical permission for the present study (Ref.
445/2007) was obtained from the Ethical Committee at
Lund University. All patients gave written consent. Study
design, methodological and technical considerations, as
well as data presentation were based on the Reporting
Recommendations for Tumor Marker Prognostic Studies
(REMARK) criteria [23] (Additional file 1).
Tissue microarray construction
All tumours were histopathologically re-evaluated and
classified according to the WHO grading system of 2004
by a board certified pathologist (KJ). Tissue microarrays
(TMAs) were constructed as previously described [21]
using a semi-automated arraying device (TMArrayer,
Pathology Devices, Westminister, MD, USA). In brief,
two 1.0 mm cores were taken from viable, non-necrotic
areas from all primary tumours (n = 154), when possible
from different donor blocks, from matched fallopian
tubes with no evidence of histological disease (n = 38)
and peritoneal metastases (n = 33). All tumour samples
were represented in duplicate tissue cores (1 mm).
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For immunohistochemical analysis, 4 μm TMA-sections
were automatically pre-treated using the PT Link system
and then stained in an Autostainer Plus (DAKO; Glostrup,
Copenhagen, Denmark) with a polyclonal, monospecific
antibody (HPA012012; Atlas Antibodies AB, Stockholm,
Sweden) diluted 1:200. The specificity of the antibody has
been confirmed by immunofluorescence, Western blotting
and protein arrays (http://www.proteinatlas.org).
Analysis of immunohistochemical expression of andro-
gen receptor (AR), estrogen receptor (ER), progesterone
receptor (PR) and Ki67 was performed as previously
described [20,21]. KRAS mutation status was analysed
by pyrosequencing as previousy described [22].
Evaluation of PIGR expression
IHC staining was annotated by two observers (JB, SL),
blinded to clinical outcome, whereby consensus for each
core was reached in estimated percentage groups as
follows: 0 (0%), 1 (1-25%), 2 (25-50%), 3 (50-75%) and 4
(75-100%) stained cells. Staining intensity was annotated
in groups of 0-3, whereby 0 = negative, 1 = weak, 2 =mod-
erate and 3 = strong intensity. A multiplier of intensity and
fraction, cytoplasmic score (CS), was calculated for each
core and a mean value of the two cores was used in the
analyses.
Statistics
Mann-Whitney U test was used to assess distribution
differences in continuous PIGR expression described by
means of its median and range values in relation to clini-
copathological characteristics and investigative factors.
Classification and regression tree (CRT) analysis was
used to find the optimal cutoff value and the prognostic
impact was also validated using ROC curve analysis.
Kaplan-Meier analysis and log rank test were used to
analyse the difference in overall survival (OS) and ovar-
ian cancer specific survival (OCSS) in relation to high
and low PIGR expression as determined by CRT ana-
lysis. Cox regression proportional hazard models were
used to estimate hazard ratios (HRs) for death from
ovarian cancer or overall causes according to high and
low PIGR expression in both uni- and multivariable
analysis, adjusted for age, stage and grade.
All calculations were performed using SPSS version 21.0
(SPSS Inc, Chicago, IL). All statistical tests were two-sided
and p-values < 0.05 were considered statistically significant.
Results
Distribution of PIGR expression in fallopian tubes, EOC
and omental metastases
Thirty-six (94.7%) of the 38 sampled fallopian tubes were
suitable for analysis and PIGR expression was evident in
all cases, with a median CS of 8 (range 3.5 - 12). A totalnumber of 153 (99.4%) primary tumours and 31/33 (93.9%)
metastases were suitable for analysis, with a median CS of 5
(range 0 - 12) in the former, and 5 (range 0 - 8) in the latter.
Sample images are shown in Figure 1. PIGR expression
was significantly higher in fallopian tubes compared
to primary tumours (p = 0.0009) and to metastases (p =
0.0004, Figure 2). There was no significant difference in
PIGR expression between primary tumours and metas-
tases (p = 0.835, Figure 2). As samples from all three
locations were only available for six patients, this study
did not allow for a meaningful analysis of PIGR expres-
sion related to individual tumour progression.
PIGR expression was significantly lower in carcinomas
of the serous subtype compared to the mucinous subtype
(p = 0.009), and to other subtypes (p = 0.002, Figure 3A).
A borderline significant difference in distribution was
observed between serous and endometrioid tumours
(p = 0.060, Figure 3A). PIGR expression was significantly
lower in serous compared to non-serous carcinomas
(p <0.001, Figure 3B).
The distribution of the total PIGR score in primary
tumours is shown in Additional file 2.
Associations of PIGR expression with clinicopathological
characteristics
Associations between PIGR expression in primary tumours
and established clinicopathological and investigative pa-
rameters are shown in Table 1. High PIGR expression
was significantly associated with low grade (p = 0.001),
mucinous histological subtype (p = 0.002), positive PR
expression (p = 0.009) and negative or low Ki-67 ex-
pression (p = 0.003). Moreover, PIGR expression was
borderline significantly associated with KRAS mutation
(p = 0.061). No associations were found between PIGR
expression and age, clinical stage or expression of AR
or ER.
Prognostic significance of PIGR expression
CRT analysis established an optimal cutoff point at
CS ≤ 8.5, which was used to stratify patients into groups of
low (CS ≤ 8.5, n = 130) and high PIGR expression (CS >
8.5, n = 23), and the same prognostic cutoff was derived
from ROC curve analysis (Additional file 3). Kaplan-Meier
analysis of the entire cohort (n = 153) demonstrated a sig-
nificantly prolonged OS (p = 0.013) and OCSS (p = 0.009)
for patients with tumours displaying high PIGR expression
(Figure 4). Univariate Cox regression analysis confirmed
the relationship between high PIGR expression and a pro-
longed OS (HR = 0.478; 95% CI 0.263-0.868; p = 0.015)
and OCSS (HR = 0.431; 95% CI 0.225-0.825; p = 0.011).
However, these associations did not remain significant in
multivariable analysis, adjusted for age, grade and clinical
stage (data not shown). Analysis in strata according to
histological subtype revealed that the prognostic impact of
Figure 1 Immunohistochemical images of PIGR staining in fallopian tubes, primary and metastatic epithelial ovarian cancer. Sample
images (10× magnification) representing immunohistochemical expression of PIGR, described as cytoplasmic score, i.e. a multiplier of fraction
(0-4) and intensity (0-3) of staining: (A) Fallopian tube and (B) primary tumour with strong expression (score 12 and 12, respectively), (C) primary
tumour with weak (score 3) and (D) matched metastasis with negative expression (score 0).
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subtype (data not shown). Continuous PIGR expression
was not significantly associated with clinical outcome
(data not shown). Associations of high and low PIGR
expression, defined by the CRT-derived cutoff , with clini-
copathological factors were similar to comparisons of theFigure 2 Distribution of PIGR expressions in fallopian tubes,
primary tumours and metastases. Box plot visualising the staining
distribution of PIGR in fallopian tubes, primary tumours and metastases.
PIGR expression is described as cytoplasmic score, i.e. a multiplier of
fraction (0-4) and intensity (0-3) of staining.distribution of the continuous PIGR score across categor-
ies (data not shown).
Discussion
This study is, to the best of our knowledge, the first to in-
vestigate the expression, clinicopathological correlates and
prognostic significance of PIGR in EOC. In addition, PIGR
expression was evaluated in a subset of matched benign-
appearing fallopian tubes and omental metastases.
The results demonstrate a significantly higher PIGR
expression in fallopian tubes compared to primary and
secondary tumour sites. Recent studies have suggested
that a significant proportion of serous carcinomas arise
within the fimbrial tubal epithelium [24,25]. Our findings
indicate that malignant transformation could involve a
downregulation of PIGR in EOC cases. PIGR expression
in primary and metastatic tumours was rather similar,
suggesting that downregulation of PIGR occurs early in
ovarian carcinogenesis. Previous studies have suggested
that omental spreading of EOC is due to wall shear
stress in tumours as a result of fluid flow in the periton-
eum or peristaltic movements [26,27], rather than from
traditional metastasis-models such as haematogenous
or lymphatic seeding, and thus, metastasising might not
only occur due to tumour progression. This might
explain why PIGR expression did not differ between pri-
mary and metastatic tumours. However, as this study
Figure 3 Distribution of PIGR expression in histological
subtypes. Box plots visualising (A) the staining distribution of PIGR
in different histological subtypes and (B) in serous vs non-serous
carcinomas. PIGR expression is described as cytoplasmic score, i.e. a
multiplier of fraction (0-4) and intensity (0-3) of staining.
Table 1 Associations between PIGR expression and
clinicopathological and investigative parameters
Factor PIGR expression p-value
median (range)
Age
≤Median 4.00 (0.00–12.00) 0.258
>Median 5.00 (0.00–12.00)
Histological subtype





Low 6.00 (0.00–12.00) 0.001
High 4.00 (0.00–12.00)
Clinical stage





Wild–type 4.25 (0.00–12.00) 0.061
Mutated 6.75 (2.00–12.00)
Ki–67




Negative 5.00 (0.00–12.00) 0.674
Positive 4.00 (0.00–12.00)
ER
Negative 6.00 (0.00–12.00) 0.089
Positive 4.00 (0.00–12.00)
PR
Negative 4.00 (0.00–12.00) 0.009
Positive 6.50 (0.00–12.00)
AR = androgen receptor, ER = oestrogen receptor, PR = progesterone receptor.
The analysis of PIGR expression is based on multipliers of staining intensity
and fraction of tissue stained (cytoplasmic score).
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locations, further studies are needed to analyse PIGR
expression related to individual tumour progression.
There were no significant associations between PIGR
expression and clinical stage or age, which is in line
with previous studies in oesophageal [7], bladder [13]
and non-small cell lung cancer [10]. PIGR expression
was found to be significantly associated with positive
PR status, negative or low Ki-67 expression and border-
line significantly associated with KRAS-mutation. High
expression of Ki-67 has previously been described to
correlate with more advanced tumour stage and peri-
toneal spread [28], whereas KRAS mutation reportedly
is associated with well-differentiated EOC tumours
[22]. Lee et al. reported PR to be an independent predictor
of good prognosis [29]. However, another study analysed
PR status in strata according to different histological sub-
types, whereby no correlation with prognosis was found[21]. Nevertheless, the findings of the present study sug-
gest an association between high PIGR expression and a
less malignant phenotype, reflected in the associations
with the described clinicopathological parameters as
well as a more favourable clinical outcome
Similar associations have previously been described in
studies on PIGR expression in oesophageal [7], colorec-
tal [9], non-small cell lung [10], endometrial [11] and
bladder cancer [13].
Figure 4 Kaplan-Meier estimates of ovarian cancer specific and overall survival in all patients according to PIGR expression. Kaplan
Meier analysis of (A) overall survival and (B) ovarian cancer specific survival in strata of low and high PIGR expression. The categories of staining
were determined by classification and regression tree analysis based on the cytoplasmic score (CS), whereby low expression = CS≤ 8.5 and
high expression = CS > 8.5.
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nosis in patients with tumours displaying high expres-
sion of PIGR has been suggested. One study speculated
that overexpression of PIGR may be part of the host’s re-
sponse to the presence of cancer cells or to carcinogenic
stimulus [11]. This explanation originates from the fact
that SC, a cleaved form of PIGR, is a known inhibitor of
proinflammatory cytokine IL-8 and, as a consequence, of
polymorphonuclear neutrophils (PMNs) [11]. Although
PMNs are generally accepted as being antitumorigenic
[11], Dong et al. reported PMNs facilitating extrava-
sation of melanoma cells [30]. The study also described a
reduced tumour extravasation by IL-8 receptor-blocking
or neutralisation of soluble IL-8 [30]. Additionally, PMNs
have been described to promote tumour progression by
activating matrix metalloproteinase-2 (MMP-2), a pro-
teinase involved in angiogenesis, tumour invasion and
metastasis [11,31]. Thus, high levels of SC may reduce
the occurrence of metastases and prevent tumour-
induced angiogenesis and tumour invasiveness. How-
ever, studies on colorectal [32] and hepatocellular [33]
cancer suggest that SC serum levels are not necessarily
associated with tumour-specific PIGR expression and
the described association might therefore not be applic-
able for the present study.
A limitation to this study is the lack of information on
residual tumour after surgery, however, as PIGR expres-
sion did not provide any independent prognostic value,
inclusion of this information in the multivariable modelis not likely to have altered our findings. Future studies
of PIGR expression in EOC should nonetheless, when
possible, incorporate this factor in multivariable models.
Another limitation was the subjective nature of IHC
staining assessment. In order to avoid bias, the TMAs
were not sorted by differentiation or histological sub-
type. The observers were blinded to clinical outcome,
and any scoring differences were discussed in order to
reach consensus. To further decrease the impact of sub-
jectivism, image analysis software could have been an
option [34]. However, the specificity and sensitivity of
automated software are still unclear [35] and therefore, a
semiquantitative assessment strategy was deemed more
appropriate. Tissue heterogeneity might also pose a diffi-
culty [34,36], however, to increase representativeness
and decrease influence of heterogeneity, one should in-
clude several samples from the same tissue [35,37], as
was done in this study.
While PIGR expression was found to be significantly
lower in tumours of the serous subtype compared to
non-serous tumours, its prognostic value did not differ
across subtypes. Of note, the number of some histo-
logical subtypes was rather limited in the here studied
cohort and, therefore, future studies on the prognostic
value of PIGR expression in EOC should ideally include
a larger number of samples from different subtypes. It
will also be of interest to examine PIGR expression in
relation to the recently introduced complementary clas-
sification system, wherein EOC is divided into the less
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responding to two potential main pathways of tumouri-
genesis, that differ with respect to mutation pattern and
prognosis [38].Conclusions
In this pooled, prospective population-based cohort of
epithelial ovarian cancer, significant associations were
found between PIGR expression and mucinous hist-
ology, low-grade tumours and Ki-67 expression, indicat-
ing a less aggressive phenotype for tumours displaying
high PIGR expression. Moreover, patients with high
tumour-specific expression of PIGR had a significantly
prolonged survival in unadjusted analysis, but not when
adjusted for age, grade and clinical stage. These results
are novel, and merit further study in a functional context
as well as in additional patient cohorts.Additional files
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